PPFIA4 Knockdown Suppresses Expression, Proliferation, and Migration in Colorectal Cancer Cells. by Wenliang Yuan (7842908)

“…<p>(A) qPCR analysis showing a significant reduction in PPFIA4 mRNA expression in the si-PPFIA4 group.…”

Data Sheet 1_The protective effects and mechanisms of rosmarinic acid against Pseudomonas aeruginosa infection in Caenorhabditis elegans.doc by Ying Zhang (40767)

“…RA treatment at concentrations of 100-300 mg/L dose-dependently reduced the number of PA14 colonies in the nematodes, prolonged the lifespan of the infected nematodes, improved behavioral impairments, decreased lipofuscin and ROS accumulation, and alleviated oxidative stress. …”

Table 1_Impact of recent COVID-19 infection on liver and kidney transplantation – a worldwide meta-analysis and systematic review.docx by Nicola Sariye Pollmann (22327573)

“…Nevertheless, an association was found with decreased overall survival in liver transplant recipients within the 180-day follow-up period.…”

Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.…”

Data Sheet 1_Breaking the cycle: a pilot study on autonomous Digital CBTe for recurrent binge eating.pdf by Rebecca Murphy (5514419)

“…Those who completed all sessions and the post-intervention assessment (n = 55, 50%) reported significant decreases in binge eating, eating disorder psychopathology, and secondary impairment at post-intervention. …”

Data Sheet 4_Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.pdf by Wenting Song (822582)

“…Compared with the control group, the treatment group demonstrated better performance in reducing neurological impairment score [SMD = −0.99, 95% CI −1.24, −0.73], improving overall efficacy [RR = 1.22, 95% CI 1.14, 1.30] and ADL score [SMD = 2.01, 95%CI 1.55, 2.46], as well as decreasing the cerebral hematoma volume [MD = −6.98, 95% CI −8.76, −5.20] and cerebral edema volume [MD = −3.67, 95%CI -5.27, −2.06], with statistically significant differences observed. …”

Data Sheet 3_Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.pdf by Wenting Song (822582)

“…Compared with the control group, the treatment group demonstrated better performance in reducing neurological impairment score [SMD = −0.99, 95% CI −1.24, −0.73], improving overall efficacy [RR = 1.22, 95% CI 1.14, 1.30] and ADL score [SMD = 2.01, 95%CI 1.55, 2.46], as well as decreasing the cerebral hematoma volume [MD = −6.98, 95% CI −8.76, −5.20] and cerebral edema volume [MD = −3.67, 95%CI -5.27, −2.06], with statistically significant differences observed. …”

Data Sheet 2_Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.pdf by Wenting Song (822582)

“…Compared with the control group, the treatment group demonstrated better performance in reducing neurological impairment score [SMD = −0.99, 95% CI −1.24, −0.73], improving overall efficacy [RR = 1.22, 95% CI 1.14, 1.30] and ADL score [SMD = 2.01, 95%CI 1.55, 2.46], as well as decreasing the cerebral hematoma volume [MD = −6.98, 95% CI −8.76, −5.20] and cerebral edema volume [MD = −3.67, 95%CI -5.27, −2.06], with statistically significant differences observed. …”

Data Sheet 1_Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.pdf by Wenting Song (822582)

“…Compared with the control group, the treatment group demonstrated better performance in reducing neurological impairment score [SMD = −0.99, 95% CI −1.24, −0.73], improving overall efficacy [RR = 1.22, 95% CI 1.14, 1.30] and ADL score [SMD = 2.01, 95%CI 1.55, 2.46], as well as decreasing the cerebral hematoma volume [MD = −6.98, 95% CI −8.76, −5.20] and cerebral edema volume [MD = −3.67, 95%CI -5.27, −2.06], with statistically significant differences observed. …”

Table 2_Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin.doc by Xianghua Quan (21404606)

“…However, PLD is associated with adverse reactions (ADRs) such as hand-foot syndrome (HFS) and oral mucositis (OM), which have garnered significant attention. Although not life-threatening, HFS and OM can cause severe discomfort and functional impairment. …”

Data Sheet 2_Metabolomics reveals key biomarkers for ischemic stroke: a systematic review of emerging evidence.pdf by Lu Ding (475637)

“…Glycine-serine-threonine and valine-leucine-isoleucine pathways were significant in diagnosing IS and AIS, and in differentiating ischemic and hemorrhagic strokes, as well as identifying post-stroke depression and cognitive impairment.…”

Data Sheet 1_Metabolomics reveals key biomarkers for ischemic stroke: a systematic review of emerging evidence.pdf by Lu Ding (475637)

“…Glycine-serine-threonine and valine-leucine-isoleucine pathways were significant in diagnosing IS and AIS, and in differentiating ischemic and hemorrhagic strokes, as well as identifying post-stroke depression and cognitive impairment.…”

Data Sheet 3_Metabolomics reveals key biomarkers for ischemic stroke: a systematic review of emerging evidence.pdf by Lu Ding (475637)

“…Glycine-serine-threonine and valine-leucine-isoleucine pathways were significant in diagnosing IS and AIS, and in differentiating ischemic and hemorrhagic strokes, as well as identifying post-stroke depression and cognitive impairment.…”

Data Sheet 4_Metabolomics reveals key biomarkers for ischemic stroke: a systematic review of emerging evidence.pdf by Lu Ding (475637)

“…Glycine-serine-threonine and valine-leucine-isoleucine pathways were significant in diagnosing IS and AIS, and in differentiating ischemic and hemorrhagic strokes, as well as identifying post-stroke depression and cognitive impairment.…”

Table 1_Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin.doc by Xianghua Quan (21404606)

“…However, PLD is associated with adverse reactions (ADRs) such as hand-foot syndrome (HFS) and oral mucositis (OM), which have garnered significant attention. Although not life-threatening, HFS and OM can cause severe discomfort and functional impairment. …”

Table 3_Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin.doc by Xianghua Quan (21404606)

“…However, PLD is associated with adverse reactions (ADRs) such as hand-foot syndrome (HFS) and oral mucositis (OM), which have garnered significant attention. Although not life-threatening, HFS and OM can cause severe discomfort and functional impairment. …”